Sign In
Buy CLPBY
$5.93
+0.0245 (+0.415%)
At Close: Jun 03, 2026
Coloplast: Went 'BUY' A Bit Early
10:37am, Saturday, 16'th May 2026
Coloplast is rebased to a 20x P/E with a new price target of 490 DKK, reflecting a more realistic valuation post-premiumization. Recent setbacks—the Kerecis acquisition write-down, product recalls,
Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript
12:10pm, Tuesday, 12'th May 2026
Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript
Coloplast A/S (CLPBY) Q4 2026 Guidance Call Transcript
09:03am, Friday, 24'th Apr 2026
Coloplast A/S (CLPBY) Q4 2026 Guidance Call Transcript
Comparing Coloplast A/S (OTCMKTS:CLPBY) & Bluejay Diagnostics (NASDAQ:BJDX)
01:13am, Friday, 03'rd Apr 2026
Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and Bluejay Diagnostics (NASDAQ: BJDX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies
Coloplast: The Market Is Throwing Away A High-Quality Compounder
07:41am, Tuesday, 17'th Mar 2026
Coloplast is now a clear Buy, trading nearly 60% below its all-time high and at historically low valuation multiples. CLPBF's wide economic moat, underpinned by patents and high switching costs, suppo
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
02:25pm, Wednesday, 11'th Mar 2026
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons.
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
05:48pm, Sunday, 08'th Mar 2026
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast appoints Gavin Wood as new CEO
01:52pm, Wednesday, 04'th Mar 2026
Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief
CLPBY or PEN: Which Is the Better Value Stock Right Now?
12:40pm, Tuesday, 24'th Feb 2026
Investors with an interest in Medical - Instruments stocks have likely encountered both Coloplast A/S Sponsored ADR (CLPBY) and Penumbra (PEN). But which of these two stocks offers value investors a b
Reviewing OPKO Health (NASDAQ:OPK) and Coloplast A/S (OTCMKTS:CLPBY)
02:32am, Thursday, 12'th Feb 2026
Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based
Coloplast A/S - Updated Financial Calendar 2025-26
09:36am, Wednesday, 11'th Feb 2026
Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General
Coloplast A/S (OTCMKTS:CLPBY) Shares Gap Down – What’s Next?
02:58am, Sunday, 08'th Feb 2026
Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY - Get Free Report)'s share price gapped down prior to trading on Friday. The stock had previously closed at $8.38, but opened at $7.83. Coloplast A/S shares
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
03:04pm, Friday, 06'th Feb 2026
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
Coloplast A/S - Interim Financial Report, Q1 2025/26
09:46am, Friday, 06'th Feb 2026
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew
Coloplast A/S - Interim Financial Report, Q1 2025/26
01:30am, Friday, 06'th Feb 2026
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0
